AbCellera Biologics Inc (NASDAQ:ABCL) currently has a daily average trading volume of 2.17M but it saw 1426212 shares traded in last market. With a market cap of 803.40M USD, the company’s current market price of $2.72 came rising about 1.87 while comparing to the previous closing price of $2.67. In past 52 weeks, the stock remained buoying in the range of price level as high as $6.05 and as low as $2.34. In the recent trading on the day, stock has struck highest price mark of $2.61 while lowest mark touched by it was $2.77.
Taking a look at 20-day trading activity of AbCellera Biologics Inc (ABCL) gives us an average price of $2.78, while its current price level is -55.08% below from 52-week high level whereas it is 16.49% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.69 while that of 200 days or SMA-200 reads an average of $3.45. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.24% during that period while stretching the period over a month that increases to 6.37%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 49.01 which implies that the stock is in neutral territory.
The Benchmark Company upgraded its recommendation for the stock as a “Buy” from “Hold” on February 22, 2024 while assigning a price target of $9. KeyBanc Capital Markets issued its recommendations for the stock as it initiated the price target for the stock is $6.
Over the week, ABCL’s stock price is moving -1.45% down while it is -2.16% when we observe its performance for the past one month. Year-to-date it is -52.36% down and over the past year, the stock is showing a downside performance of -37.33%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.16 beaten by the consensus estimate of -0.12 for the same. The company is expected to be releasing its next quarterly report in December, for which analysts forecasted an EPS of -0.15 while estimate for next year EPS is -0.59. In next quarter, company is expected to be making quarterly sales of $11.81M as analysts are expecting the sales for current fiscal year at $31.58M and seeing the company making $43.12M in sales next year. Moreover, analysts are in estimates of $7.58M for current-quarter revenue.
Currently, AbCellera Biologics Inc’s total number of outstanding shares is 290.82M with 27.99% of that held by the insiders while 38.21% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -15.36% and return on equity (ROE) at -15.55%. Stock’s beta reads 0.35. Stock has a price to book (P/B) ratio of 0.74 while price to sale or P/S ratio amounts to 24.38. Its return on asset (ROA) is -12.10% on average.
